We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pfizer has initiated a Phase I study of an investigational, novel oral antiviral therapeutic, PF-07321332, for SARS-CoV-2 virus that causes Covid-19, in healthy adult subjects in the US.